Background: The timely provision and interpretation of trends in population-based cancer survival estimates is an important clinical and public health priority. Between 1990Between -1994Between and 2000Between -2004, the 5-year relative survival increased significantly in all participating registries among patients with prostate, breast, and colorectal cancers and in at least 7 of 11 registries for stomach, corpus uteri, ovarian, kidney, and thyroid cancers, as well as for non-Hodgkin's lymphoma. Projections suggest further substantial increases in survival in the calendar period [2005][2006][2007][2008][2009]. For most cancer sites amenable to effective early detection and treatment, major geographical differences persist with lower survival in Eastern European countries.
introduction
Commonly, a delay of 2-3 years in the availability of population-based cancer incidence data is generally unavoidable due to the time required to attain high completeness in the registration of recent cancer information. In a previous evaluation, it was shown that model-based period analysis, on incorporating long-term survival trends into the modelling of period relative survival estimates, enabled a reliable projection of survival estimates into the near future, compensating for the delay in the general provision of such estimates [1] .
We applied model-based period analysis to examine trends in survival and obtain up-to-date cancer survival estimates applying the latest survival analysis techniques in combination with most up-to-date cancer registry data to provide the most timely monitoring of population-based cancer survival. The work was carried out within the framework of the EUNICE Survival Working Group, a mutual effort of 12 population-based cancer registries across Europe.
materials and methods data sources
The database included relevant cancer information from 11 cancer registries with incidence and follow-up data from at least 1985 onwards. The inclusion criteria and data preparation were described in detail elsewhere [2] . Here, malignant tumours diagnosed in 1985-2004 formed the survival database, along with corresponding age, sex, and calendar period-specific life tables to enable the calculation of relative survival estimates. Table 1 provides an overview of the included registries, their underlying populations, the timeframe of the registry-specific incidence, follow-up data, and background mortality data, as utilised in this analysis.
survival analysis
Five-year relative survival estimates were calculated for selected important cancers. Relative survival estimates, which quantify cancer-related excess mortality within a cancer patient population, were derived as ratios of the observed survival of the cancer patients and the expected survival of the underlying general population [3] . The latter estimate was calculated according to the Ederer II method [4] . All derived survival estimates were period estimates, which are exclusively on the basis of the survival experience of patients during the specific calendar period for which they are derived [5] , and were shown to closely predict survival later observed for patients diagnosed in that period [6] [7] [8] .
survival trends between 1990-1994 and 2005-2009
First, 5-year relative survival estimates were calculated for the calendar periods 1990-1994, 1995-1999, and 2000-2004: after age group-specific person-time at risk and number of deaths by year of follow-up were calculated for each period separately (i.e. 1990-1994, 1995-1999, and 2000-2004) , a period-specific Poisson regression model for relative survival was used to model the excess number of deaths as a function age group (categorical variable) and follow-up year (categorical variable), using the logarithm of the person-time at risk as the offset. To derive a test of survival trends as well as projected survival estimates, the age group-specific persontime at risk and numbers of deaths by year of follow-up for the periods [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] In both the period-specific and trend analyses, in instances where registries had data available on incident cases until 2003, but follow-up of vital status until 2004, hybrid analysis was used. The method enables estimation of up-to-date survival for situations where mortality data are available for more recent periods than incidence [9, 10] . Standard errors of the survival estimates were calculated using the delta method. Alpha = 0.05 was used as level of significance for trend tests.
age adjustment
All survival estimates were age-adjusted, on the basis of five age groups (15-44, 45-54, 55-64, 65-74, 75+ years) , with the exception of prostate cancer, for which the first age group was 15-54 years, and thyroid cancer, for which only two age groups were used (15-44, 45+) . Adjustment was done by deriving weighted averages of modelled age-specific 5-year relative survival estimates, with weights from the International Cancer Survival Standards [11] . All calculations were carried out using the SAS statistical software package [12] .
sponsors
The funding source had no involvement in the carrying out this study. (Table 2) .
Among patients with stomach cancer, major increases (of between 5% and 9% units) occurred in Saarland, Slovenia, Torino, Estonia, and Tuscany. In 2000-2004, survival was highest in Saarland (37%), while estimates ranged between 33% and 24% elsewhere, but were lower in Eindhoven (21%), Cracow, and Scotland (both 18%). Projections for the calendar years 2005-2009 predict 5-year relative survival between 19% and 40% in the participating registry populations.
Increases in the survival of patients with colorectal cancer were highest, exceeding 10% units, in Cracow, Torino, Estonia, Saarland, Slovenia, and Scotland. Elsewhere, increases were original article Annals of Oncology significantly in 11, four, and nine of the total 11 populations under study, respectively (Table 4) . Among patients with prostate cancer, survival rose greatest, by 30% units, in Torino and Cracow, and by 20%-26% units in all other registries, except Eindhoven and Saarland, where rises of 17% and 15% units, respectively, were seen. By 2000-2004, the 5-year relative survival of patients, which was <60% in 7 of 11 registries in 1990-1994, rose to at least 60% in all registries: estimates were highest in Saarland and Torino (89%), between 84% and 80% in Finland, Geneva, Eindhoven, Tuscany, and Norway and at 73% in Scotland. Survival remained <70% in Estonia, Slovenia and was lowest in Cracow (60%). Projections Among patients with testicular cancer, increases in survival were more marked in Cracow (+27% units) and Estonia (+15% units), the registries with the lowest survival in 1990-1994. Elsewhere, gradual increments in survival were seen in all registries with estimates <90% in 1990-1994. Projections for 2005-2009 suggest that 5-year relative survival will reach 90% in all registries except Estonia, where survival is projected to be 82%.
Among patients diagnosed with kidney cancer, marked increases in survival occurred in Estonia and Torino (+21 and +16% units, respectively), as well as in Cracow, Saarland, Tuscany, and Scotland (10%-11% units); estimates rose by 6% to 7% units in Finland, Slovenia, and Norway. The rise in Geneva (+8% units) was not statistically significant, and survival remained essentially unchanged in Eindhoven. By Among patients with multiple myeloma, rises were marked in Tuscany, Estonia (+13% and 11% units, respectively), Scotland, and Norway (+7% and 6% units, respectively). By the 2000-2004 period, 5-year relative survival was >40% in Norway and Tuscany and ranged between 39% and 30% in all other registries, except Cracow (23%).
Among patients with leukaemia, survival rises of 10% units occurred in Norway, Scotland, Slovenia, Estonia, and Tuscany, 
trends in other common cancers
Between 1990-1994 and 2000-2004, the 5-year relative survival of patient diagnosed with lung and thyroid cancers rose significantly in 9 and 8 of the 11 registries, respectively, while among patients with skin melanoma, significant rises occurred in six and five of the registries among female and male patients, respectively (Table 6 ).
Absolute increases in survival among patients with lung cancer were generally rather modest and <5% units, except for Geneva (+7% units). Among patients diagnosed with cutaneous melanoma, survival was distinctly higher and rose more consistently among females than males. Differences between sexes were generally between 7% and 10% units by [2000] [2001] [2002] [2003] [2004] ; in this diagnosis period, estimates were highest for both sexes in Geneva (97% and 87% for females and males, respectively). Elsewhere, survival among females came close to or exceeded 90% in all but four registries (Cracow, Estonia, Slovenia, and This would suggest inadequate availability of, or access to modern, more effective forms of care for these patients. On the other hand, there has been a convergence in the survival of patients with cancers associated with good outcome if treated, such as thyroid and testicular cancers [17] , and any differences may essentially disappear by 2005-2009. Incidence, survival, and mortality trends considered together may identify true progress against cancer, often marked by improving survival alongside more favourable changes in mortality than incidence [18] [19] [20] . Patterns of change in the registry-specific age-adjusted incidence and corresponding national-level mortality rates (Table 7) between 1988-1992 and 1998-2002 suggest that the survival increases more likely reflect true progress in early diagnosis and treatment for gastrointestinal cancers, melanoma, as well as breast and corpus uteri cancer, while the mortality trends confirm a lack of progress in the tertiary prevention of lung cancer. The pattern for prostate cancer, with dramatic rises in survival and incidence in most registries, is consistent with lead time and overdiagnosis effects [21, 22] caused by the increasing utilisation of prostate-specific antigen (PSA) testing as a diagnostic tool [23, 24] .
Clinical studies have shown that for both stomach and colorectal cancers, advances in adjuvant therapy [25] [26] [27] [28] and surgical management [29] [30] [31] are important in increasing survival. For breast cancer, advances in hormonal therapy [32] [33] [34] [35] , better risk assessment of patients [36] , and earlier diagnosis through mass or opportunistic screening are likely to be key factors, while for ovarian cancer, improved quality of surgical management and centralisation of care are important [37, 38] . For prostate cancer, advances in therapy of both localised and metastatic diseases could play a role [39, 40] , but stage shift and a lengthy lead time, mainly caused by the use of PSA testing [41] likely explain much of the apparent increases in survival. In NHL, stem-cell transplantation [42] as well as antibody therapy [43] have been shown to provide better disease control; among patients with leukaemia, improvements in the diagnosis and therapy have contributed [44, 45] .
Previous analyses from collaborative international studies have suggested between-country variations in cancer survival may be largely explained by socioeconomic factors and overall health expenditures. These factors are likely to explain much of the persisting survival differences seen between Eastern and other European countries in our analysis. With increasing economic prosperity and better access to effective diagnosis and care in Eastern countries, the current survival gap could be substantially reduced. Even within the constraints of limited economic resources, improvements in survival may be achieved by actions such as concerted efforts in surgical management strategies [46] and quality control [47] in colorectal cancer, quality assurance in breast cancer-screening programmes [48] , early detection programmes for melanomas of the skin [49, 50] , increasing participation in clinical trials [51] , and specialisation of cancer care [52] .
In this paper, the combination of model-based analysis with techniques of period analysis enabled projections of survival expectations of currently diagnosed patients and thus allowed more timely monitoring of cancer survival than previous studies which primarily pertained to patients diagnosed many years ago. Clearly, the validity of the projections depends on the validity of the model assumptions, in particular the legitimacy of extrapolating trends in survival in preceding time periods. While this precondition will not always hold, extensive empirical evaluation of the method using historical data from more than half a century from one of the participating registries has shown that application of the model in the past would, on average, have provided much better predictions of survival expectations of presently diagnosed patients than other methods commonly used for population-based monitoring of cancer survival, including standard period analysis [1] .
In summary, this first model-based projection of period survival estimates for recently diagnosed patients in Europe indicates that survival remains consistently lower in Eastern European populations than elsewhere for a number of frequently diagnosed forms of cancer, including breast and colorectal cancers, melanoma of the skin, and haematological malignancies. Improving outcomes in these patient populations must remain a high priority. Model-based analysis, by enabling the projection of survival trends into the 
